New listings worth $142 million has been added to the Pharmaceutical Benefits Scheme. 
From July, more Australians can benefit from their Medicare with more affordable and available medications. 

Government subsidy is making medications such as Vorinostat (Zolinza) to treat eligible patients with relapsed or refractory cutaneous T-cell Lymphoma. Without the subsidy, it would cost patients around $20,000 per year. 

In addition, adalimumad (Humira) has become part of the listings, as it is a treatment of hidradents suppurativa, a skin disease. 

Around 400 Australians will benefit and save around $35,199 per year. 

Treatment of idiopathic pulmonary fibrosis (IPF) and pirfenidone (Esbriet) has been added to the PBS. 

IPF mainly concerns the failure of the lung function. The treatment will provide an extra option for patients. 

The subsidy allows these medications to only be $38.80 per script and $6.30 for concessional patients. 

The liberal government has added around $6 billion to the PBS since last year. 

Since July, different medications such as aripiprazole, azithromycin, diclofenac, fluvoxamine, gabapentin, modafinil and more has been added to the PBS. 

This has been a response of the Government from the Pharmaceutical Benefits Advisory Committee. 

For the full list that already came into effect at the beginning of July can be viewed here: http://www.pbs.gov.au/browse/changes .